|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.40/--
|
企业价值
202.07M
|
资产负债 |
每股账面净值
-0.00
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/04 17:58 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Tevogen Bio Holdings Inc is a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections. The company's lead product is TVGN 489, an allogeneic, genetically unmodified T cell therapy for the treatment of COVID-19 in highly vulnerable patient populations, such as the immune-compromised, elderly, and infirm, along with potential applications in Long COVID treatment and prevention. |